Russian pharmaceutical producer Bayer will invest about RUB4bn ($60m) in the full-cycle production of German drug firm Polysan's anticoagulant Xarelto (rivaroxaban). The two companies previously partnered in 2015 on the production of Gadovist, Magnevist and Ultravist at Bayer's St Petersburg facility. The latest collaboration will also see Bayer's antiviral treatment Cytoflavin manufactured at the plant.
Russian pharmaceutical producer Polysan will invest about RUB4bn ($60m) in the full-cycle production of German drug firm Bayer's anticoagulant Xarelto (rivaroxaban). The two companies previously partnered in 2015 on the production of Gadovist, Magnevist and Ultravist at Polysan's St Petersburg facility. The latest collaboration will also see Polysan's antiviral treatment Cytoflavin manufactured at the plant.